SCHEDULE 13D/A 0001582384 XXXXXXXX LIVE 1 Ordinary Shares, par value $0.0009 per share 06/26/2025 false 0002022416 G1281K122 Silexion Therapeutics Corp

12 Abba Hillel Road Ramat-Gan L3 5250606

Brian Rosenblatt (212) 468-5100 888 Seventh Avenue New York NY 10106 0001582384 N Wildcat Capital Management, LLC OO N DE 0 113428 0 113428 113428 N 1.3 IA Row 13. Based on 8,692,392 ordinary shares, par value $0.0009 per share, outstanding as of May 30, 2025, as reported by Silexion Therapeutics Corp in its Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on June 16, 2025. 0001633223 N Wildcat Partner Holdings, LP OO N TX 0 113428 0 113428 113428 N 1.3 PN Row 13. Based on 8,692,392 ordinary shares, par value $0.0009 per share, outstanding as of May 30, 2025, as reported by Silexion Therapeutics Corp in its Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on June 16, 2025. 0001476217 N Leonard A. Potter OO N X1 0 113428 0 113428 113428 N 1.3 IN Row 13. Based on 8,692,392 ordinary shares, par value $0.0009 per share, outstanding as of May 30, 2025, as reported by Silexion Therapeutics Corp in its Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on June 16, 2025. Ordinary Shares, par value $0.0009 per share Silexion Therapeutics Corp 12 Abba Hillel Road Ramat-Gan L3 5250606 EXPLANATORY NOTE Except as set forth in this Amendment No. 1 (this "Amendment"), the initial Schedule 13D (the "Original 13D") that was filed on August 22, 2024, remains in effect, and capitalized terms used herein but not defined herein have such respective meanings, as defined in such Original 13D. The information set forth in response to the Item below shall be deemed to be a response to all Items where such information is relevant. The information set forth in the Exhibits to the Original 13D is expressly incorporated herein by reference and the response to each Item of this Statement is qualified in its entirety by the provisions of such Exhibits. The Reporting Persons are filing this Amendment to reflect its new percentage beneficial ownership in the Issuer, which has decreased as a result of an increased in the number of shares of outstanding Ordinary Shares of the Issuer. Paragraphs (a), (b) and (e) of Item 5 of the Original 13D are hereby amended and restated in their entirety as follows: The information contained in rows 7, 8, 9, 10, 11 and 13 on each of the cover pages of this Statement is incorporated by reference in its entirety into this Item 5. (a), (b) The percentage of Ordinary Shares beneficially owned by the Reporting Persons is based 8,692,392 Ordinary Shares outstanding as of May 30, 2025, as reported by the Issuer in its Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on June 16, 2025. Each of the Reporting Persons has the power to vote and dispose of the Ordinary Shares beneficially owned by such entity (as described above), and each of the Reporting Persons expressly disclaims beneficial ownership of any Ordinary Shares not owned directly by it except to the extent of any pecuniary interest therein. Wildcat Capital, as the investment manager of the WPH, has the authority to vote and dispose of all of the Ordinary Shares reported in this Schedule 13D, but expressly disclaims beneficial ownership of any Ordinary Shares not owned directly by it except to the extent of its pecuniary interest therein. Each Reporting Person expressly disclaims beneficial ownership of any securities reported herein except to the extent such Reporting Person actually exercises voting or dispositive power with respect to such securities and except to the extent of such Reporting Person's pecuniary interest therein. See item 5(a). January 17, 2025 Exhibit 99.3. Amended and Restated Schedule A Wildcat Capital Management, LLC /s/Leonard A. Potter 06/26/2025 Wildcat Partner Holdings, LP /s/Sherri Conn 06/26/2025 Leonard A. Potter /s/Leonard A. Potter 06/26/2025